Investor Relations
Abcam IR Home
Share price & chart
Reports & accounts / Financial Calendar
Regulatory news (RNS)
Contacts & advisors
Governance
CSR statement
Directors
Major shareholders
Other Documents
The Abcam story
About research antibodies
Abcam company news
Main Abcam website

REG-ABCAM Plc Director/PDMR Shareholding

http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20091109:RnsI2318C
                                                                                                                       .
RNS Number : 2318C  
  
ABCAM Plc  
  
09 November 2009  
  
 
  For immediate release   9November 2009  
  
  
ABCAM PLC  
  
("Abcam" or "the Company")  
  
Director/PDMR Dealings: LTIP  
  
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that 
markets antibodies via its own online catalogue, announces that on 9 November 
2009 the Remuneration Committee granted the following conditional nil cost share 
awards at a price of 904 pence per ordinary share (the closing share price on 6 
November 2009) to the Executive Directors of the Company under the Abcam plc 
Long-Term Incentive Plan (the "LTIP"):  
  
 
  Name              Number of Ordinary Shares subject to the   
                    LTIP Award                                 
  Jonathan Milner   27,399                                     
  Jim Warwick       24,744                                     
  Jeff Iliffe       23,416                                     
  
  
The shares subject to the LTIP awards issued to Executive Directors will be 
released in three years' time subject to continued employment and subject to the 
satisfaction of certain specific performance conditions based on:  
  
 
 * the Company's Comparative Total Shareholder Return performance against a 
Comparator Group of companies; and  
 * growth in Earnings per Share.  
  
In addition, the following PDMRs were also granted LTIP awards in accordance 
with the rules of the LTIP:  
  
 
  Name              Number of Ordinary Shares subject to the   
                    LTIP Award                                 
  Mark Bushfield    8,151                                      
  Jane Cooke        2,895                                      
  Philippe Cotrel   8,151                                      
  
  
The shares subject to the LTIP awards issued to PDMRs will vest in three years' 
time subject to the achievement of specific performance criteria.  
  
For further information please contact:  
  
 
  Abcam                                               + 44 (0) 1223 696000   
  Jonathan Milner, Chief Executive Officer                                   
  Jeffrey Iliffe, Chief Financial Officer                                    
                                                                             
  Numis Securities                                    + 44 (0) 20 7260 1000  
  Michael Meade / Nick Westlake - Nominated Adviser                          
  James Black - Corporate Broking                                            
                                                                             
  Buchanan Communications                             + 44 (0) 20 7466 5000  
  Mark Court / Stasa Filiplic                                                
  
  
Notes for editors:  
  
About Abcam plc  
  
Abcam is a producer and distributor of research-grade antibodies headquartered 
in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA, 
Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and 
trades under the ticker symbol ABC. The Company produces and distributes its own 
and third-party produced antibodies to academic and commercial users throughout 
the world. Product ordering is available through the Company's website 
www.abcam.com, where customers are also able to access up-to-date and detailed 
technical product data sheets. All the antibodies are sold under the Abcam brand 
name and the Company's vision is to build the world's largest online resource of 
high-quality and commercially viable antibodies. Abcam now has an online 
catalogue of over 56,000 products, most of which are antibodies, from over 250 
suppliers and employs 243 staff in its four operating companies.    
  
 
This information is provided by RNS  
  
The company news service from the London Stock Exchange  
  
  END  
  
RDSVKLFBKFBBFBX  
  

---

back to RNS news